Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Covidien unveils new tube design trial data

Covidien unveils new tube design trial data

3rd February 2009

Covidien’s new Mallinckrodt SealGuard Evac tube design has been found to reduce microaspiration by at least 95 per cent, according to a study.

Published in the American Journal of Respiratory and Critical Care Medicine, data from an eight-month randomised clinical trial found it also lowered the risk of ventilator-associated pneumonia (VAP) by 62 per cent, in comparison to a conventional endotracheal tube.

The study involved 280 patients and was conducted at Hospital Universitario de Canarias in Tenerife, Spain.

Vice-president of Covidien’s medical affairs Roger Mecca said the technological advances in the new tube could “significantly enhance” the ability to address serious complications.

He added: “Two such complications, VAP and tracheal mucosal damage, not only contribute to adverse clinical outcomes, but also have a negative financial impact on the hospital and the healthcare system.”

Currently employing 41,000 people in over 140 countries, Covidien reported revenue in 2008 of nearly $10 billion (7.05 billion pounds).

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.